{
  "paper_id": "PMC9369058",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369058/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "MiRNA sponging by circRNAs and lncRNAs. The central dogma proposes that protein-coding regions of the genome give rise to mRNAs, which are, in turn, translated into proteins. However, miRNAs, which are transcribed from the non-coding genome, could bind mRNAs via MREs and inhibit their translation. LncRNAs and, circRNAs, which are also transcribed from the non-coding genome, could bind and sponge miRNAs since they harbor MREs, resulting in the translation of the previously miRNA-inhibited mRNAs into proteins. MRE: MicroRNA response element. Figure was created with BioRender.com (accessed date: 24 July 2022).",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/03b69f731c1e/ijms-23-08351-g001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/03b69f731c1e/ijms-23-08351-g001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/03b69f731c1e/ijms-23-08351-g001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/03b69f731c1e/ijms-23-08351-g001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-23-08351-f001",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/03b69f731c1e/ijms-23-08351-g001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9369058/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/03b69f731c1e/ijms-23-08351-g001.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "The exosomal ncRNAs-mediated switch of BC cells from drug sensitivity to resistance. (A) Co-culture of drug-resistant with drug-sensitive cells leads to an exosomal ncRNAs-mediated switch into drug resistance. (B) Culture of drug-sensitive cells in drug-resistant BC-cells-conditioned media, which contains drug-resistant cell-secreted exosomes, leads to an exosomal ncRNAs-mediated switch into drug resistance.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/f653c02c6379/ijms-23-08351-g002.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/f653c02c6379/ijms-23-08351-g002.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/f653c02c6379/ijms-23-08351-g002.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/f653c02c6379/ijms-23-08351-g002.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-23-08351-f002",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/f653c02c6379/ijms-23-08351-g002.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9369058/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/f653c02c6379/ijms-23-08351-g002.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "The breast cancer exosomal lncRNA/circRNA-miRNA-target axis.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/35166ae87548/ijms-23-08351-g003.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/35166ae87548/ijms-23-08351-g003.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/35166ae87548/ijms-23-08351-g003.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/35166ae87548/ijms-23-08351-g003.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-23-08351-f003",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/35166ae87548/ijms-23-08351-g003.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9369058/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/35166ae87548/ijms-23-08351-g003.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Figure 4.",
      "caption": "Strongly experimentally validated shared target genes downstream of the BC exosomal lncRNA/circRNA-miRNA-target axis. Green nodes indicate genes and blue nodes indicate miRNAs. Minimum miRNA threshold = 2.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/8bd9293d49c3/ijms-23-08351-g004.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/8bd9293d49c3/ijms-23-08351-g004.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/8bd9293d49c3/ijms-23-08351-g004.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/8bd9293d49c3/ijms-23-08351-g004.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-23-08351-f004",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/8bd9293d49c3/ijms-23-08351-g004.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9369058/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/8bd9293d49c3/ijms-23-08351-g004.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Figure 5.",
      "caption": "Strongly and weakly experimentally validated BC-related shared target pathways downstream of the BC exosomal lncRNA/circRNA-miRNA-target axis. Orange nodes indicate pathways and blue nodes indicate miRNAs. Minimum miRNA threshold = 4. Only BC-related pathways are shown.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/72933db696d3/ijms-23-08351-g005.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/72933db696d3/ijms-23-08351-g005.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/72933db696d3/ijms-23-08351-g005.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/72933db696d3/ijms-23-08351-g005.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-23-08351-f005",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/72933db696d3/ijms-23-08351-g005.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9369058/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/72933db696d3/ijms-23-08351-g005.jpg"
    },
    "figure_6": {
      "figure_number": "Figure 6",
      "title": "Figure 6.",
      "caption": "Implication of the strong experimentally validated shared target genes downstream of the BC exosomal lncRNA/circRNA-miRNA-target axis in BC KEGG pathway. Eight out of the twenty shared target genes were found to be implicated in BC KEGG pathway. Red stars indicate the shared target genes. Red font color indicates signature genetic alterations.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/343d07b5ed14/ijms-23-08351-g006.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/343d07b5ed14/ijms-23-08351-g006.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/343d07b5ed14/ijms-23-08351-g006.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/343d07b5ed14/ijms-23-08351-g006.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ijms-23-08351-f006",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/343d07b5ed14/ijms-23-08351-g006.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9369058/images/figure_6.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e99/9369058/343d07b5ed14/ijms-23-08351-g006.jpg"
    }
  },
  "claims": [
    {
      "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 6,
    "claims_count": 80,
    "images_downloaded": 6,
    "tables_filtered": 15
  }
}